Continuing our blog series into the intricacies of transporting Cell & Gene Therapies, we look at viral vectors. You can read previous blogs here: Introduction, site qualification and apheresis.
Viral vectors represent one of the most challenging aspects of cold chain transport for Cell and Gene Therapies. These tiny powerhouses are microscopic delivery drivers, which drop genetic blueprints into cells to fight disease. Three types typically rule the CGT space: Retro Viral Vectors (RVV), Lenti Viral Vectors (LVV), and Adeno-Associated Viruses (AAV). In cell therapy, RVV and LVV are raw materials alongside patient apheresis; in gene therapy, AAV is the final drug product patients get infused with.
Given their importance, it’s perhaps no surprise that vectors are gold dust: supply is tight, costs are steep, and shipping them can be a logistical tightrope.
What Is a Vector and How Is It Made?
As already implied, cost of goodsare eye-watering. RVV’s upwards of $50,000 a dose, LVV’s upwards of $100,000, AAV’s a jaw-dropping $300,000. Cost of Good Sold for the final product goes beyond eye-watering and becomes eye-popping. Any errors in shipping come at a high cost.
Maintaining Ultra-Cold Temperatures
At a high level, viral vector production follows a similar principle across the main vector types. It starts with a virus that has been modified to remove the pathogenic genetic material and replace it with therapeutic genetic material designed to help treat disease. In cell therapy, retroviral vectors and lentiviral vectors are commonly used, while gene therapy often relies on adeno-associated viral vectors. Once engineered, these vectors are expanded in cell culture, processed and then frozen, typically at ultra-low temperatures of around -80°C, to preserve stability until they are needed.
The challenge is keeping vectors consistently below -65°C to help protect stability and viability. Dry ice is an established solution, but it brings its own risks if the pack-out and shipper design are not properly controlled. One key issue is supercooling. As CO2 gas from the dry ice moves through and out of the shipper, areas of the system can fall below -80°C, even though dry ice itself is around -78.5°C. This can accelerate sublimation, reduce the amount of dry ice covering the payload and shorten the validated duration of the shipper. If the payload is no longer properly surrounded by dry ice, temperatures can then rise above the required threshold, putting the shipment at risk.
Qualification issues can often be traced back to this point. In some cases, most shippers may perform as expected, while one appears to warm too quickly. Supercooling can be a factor in these variations. CCT’s shipper designs, including the KTEvolution and EcoFlex 3 line of dry ice shipper, are intended to help manage this risk and extend validated duration by preventing super cooling. The same design principles are also being applied across other dry ice shipper lines.
Conclusion
Transporting viral vectors brings together several of the defining challenges of cell and gene therapy logistics: ultra-low temperature control, high product value, limited supply and little room for error. While this stage may be more contained than some other parts of the vein-to-vein journey, it is still critical. Decisions around frozen shipping, pack-out design, duration, monitoring and supercooling control all have a direct impact on product viability and shipment success.
That is where specialist cold chain expertise becomes important. By understanding both the technical requirements of viral vector shipping and the operational pressures faced by therapy developers, logistics providers can help reduce risk and support more reliable delivery. Ultimately, maintaining the integrity of these shipments is about more than protecting valuable material. It helps ensure that advanced therapies can reach the patients who depend on them.
